Concepts (222)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Graves Ophthalmopathy | 7 | 2023 | 117 | 2.210 |
Why?
|
Orbital Diseases | 5 | 2018 | 181 | 2.110 |
Why?
|
Eyelid Neoplasms | 4 | 2019 | 94 | 2.060 |
Why?
|
Conjunctival Neoplasms | 4 | 2017 | 79 | 1.770 |
Why?
|
Scleral Buckling | 3 | 2022 | 84 | 1.670 |
Why?
|
Eyelid Diseases | 4 | 2018 | 155 | 1.600 |
Why?
|
Orbit | 6 | 2022 | 426 | 1.540 |
Why?
|
Orbital Neoplasms | 5 | 2022 | 225 | 1.440 |
Why?
|
Eyelids | 8 | 2022 | 265 | 1.140 |
Why?
|
Polyhydroxyethyl Methacrylate | 3 | 2022 | 31 | 1.100 |
Why?
|
Eye Infections, Bacterial | 3 | 2018 | 235 | 1.060 |
Why?
|
Eye Neoplasms | 2 | 2017 | 313 | 0.990 |
Why?
|
Sebaceous Gland Neoplasms | 2 | 2022 | 39 | 0.980 |
Why?
|
Retinal Detachment | 3 | 2022 | 411 | 0.900 |
Why?
|
Ophthalmologic Surgical Procedures | 5 | 2019 | 349 | 0.860 |
Why?
|
Lacrimal Apparatus Diseases | 3 | 2018 | 65 | 0.830 |
Why?
|
Panuveitis | 1 | 2022 | 32 | 0.820 |
Why?
|
Adenocarcinoma, Sebaceous | 1 | 2022 | 21 | 0.820 |
Why?
|
Granular Cell Tumor | 1 | 2022 | 51 | 0.810 |
Why?
|
Oxazolone | 1 | 2020 | 60 | 0.750 |
Why?
|
Orbital Myositis | 1 | 2020 | 20 | 0.750 |
Why?
|
Sweat Gland Neoplasms | 2 | 2022 | 108 | 0.720 |
Why?
|
Chalazion | 1 | 2019 | 13 | 0.700 |
Why?
|
Impetigo | 1 | 2018 | 8 | 0.660 |
Why?
|
Eye Infections, Viral | 2 | 2016 | 57 | 0.650 |
Why?
|
Nasolacrimal Duct | 2 | 2018 | 74 | 0.630 |
Why?
|
Osteochondroma | 1 | 2017 | 47 | 0.600 |
Why?
|
Calcium Compounds | 1 | 2017 | 34 | 0.600 |
Why?
|
Eccrine Glands | 1 | 2017 | 45 | 0.590 |
Why?
|
Abscess | 1 | 2021 | 607 | 0.580 |
Why?
|
Carcinoma, Squamous Cell | 3 | 2017 | 4034 | 0.580 |
Why?
|
Rhytidoplasty | 1 | 2017 | 60 | 0.560 |
Why?
|
Blepharitis | 1 | 2016 | 36 | 0.560 |
Why?
|
Dermatitis | 1 | 2018 | 197 | 0.550 |
Why?
|
Herpes Zoster Ophthalmicus | 1 | 2016 | 36 | 0.550 |
Why?
|
Myofibromatosis | 1 | 2016 | 30 | 0.550 |
Why?
|
Blepharoplasty | 2 | 2014 | 50 | 0.550 |
Why?
|
Choristoma | 1 | 2018 | 213 | 0.550 |
Why?
|
Myofibroma | 1 | 2016 | 50 | 0.530 |
Why?
|
Lymphoma, B-Cell, Marginal Zone | 1 | 2017 | 180 | 0.530 |
Why?
|
Paranasal Sinus Diseases | 1 | 2016 | 116 | 0.530 |
Why?
|
Neuroectodermal Tumors, Primitive | 1 | 2016 | 140 | 0.520 |
Why?
|
Corneal Neovascularization | 1 | 2017 | 188 | 0.520 |
Why?
|
Skin Ulcer | 1 | 2016 | 120 | 0.510 |
Why?
|
Conjunctival Diseases | 1 | 2016 | 122 | 0.500 |
Why?
|
Conjunctiva | 1 | 2018 | 494 | 0.490 |
Why?
|
Keratitis | 1 | 2017 | 268 | 0.470 |
Why?
|
Carcinoma, Basal Cell | 1 | 2019 | 545 | 0.460 |
Why?
|
Communicable Diseases | 1 | 2022 | 880 | 0.450 |
Why?
|
Cysts | 2 | 2016 | 678 | 0.450 |
Why?
|
Veins | 1 | 2018 | 770 | 0.450 |
Why?
|
Rhabdomyosarcoma | 1 | 2016 | 382 | 0.450 |
Why?
|
Lymphoma, Mantle-Cell | 1 | 2016 | 233 | 0.450 |
Why?
|
Graves Disease | 1 | 2015 | 242 | 0.440 |
Why?
|
Eyebrows | 1 | 2013 | 28 | 0.440 |
Why?
|
Oculomotor Muscles | 3 | 2022 | 371 | 0.430 |
Why?
|
Cicatrix | 1 | 2018 | 764 | 0.420 |
Why?
|
Pseudomonas Infections | 1 | 2016 | 613 | 0.410 |
Why?
|
Biopsy | 7 | 2018 | 6756 | 0.390 |
Why?
|
Iodine Radioisotopes | 1 | 2015 | 1032 | 0.390 |
Why?
|
Immunocompromised Host | 1 | 2016 | 847 | 0.390 |
Why?
|
Sonication | 1 | 2011 | 83 | 0.380 |
Why?
|
Microbubbles | 1 | 2011 | 128 | 0.370 |
Why?
|
Retinal Neoplasms | 1 | 2011 | 144 | 0.340 |
Why?
|
Hepatitis C, Chronic | 1 | 2017 | 1031 | 0.340 |
Why?
|
Pseudomonas aeruginosa | 1 | 2016 | 1219 | 0.330 |
Why?
|
Retinoblastoma | 1 | 2011 | 318 | 0.320 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 2017 | 2232 | 0.320 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2011 | 692 | 0.300 |
Why?
|
Skin Neoplasms | 2 | 2019 | 5686 | 0.290 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2017 | 2942 | 0.290 |
Why?
|
Bone Neoplasms | 1 | 2017 | 2529 | 0.260 |
Why?
|
Surgical Flaps | 3 | 2021 | 1640 | 0.250 |
Why?
|
Humans | 50 | 2023 | 744343 | 0.250 |
Why?
|
Doxorubicin | 1 | 2011 | 2234 | 0.250 |
Why?
|
Exophthalmos | 2 | 2023 | 97 | 0.240 |
Why?
|
Limbus Corneae | 2 | 2016 | 144 | 0.240 |
Why?
|
Syringoma | 1 | 2022 | 5 | 0.220 |
Why?
|
Molecular Targeted Therapy | 1 | 2013 | 2727 | 0.200 |
Why?
|
Entropion | 1 | 2020 | 10 | 0.200 |
Why?
|
Prosthesis Implantation | 2 | 2017 | 642 | 0.190 |
Why?
|
Ectropion | 1 | 2020 | 26 | 0.190 |
Why?
|
Temporal Muscle | 1 | 2021 | 37 | 0.190 |
Why?
|
Muir-Torre Syndrome | 1 | 2020 | 13 | 0.180 |
Why?
|
Magnetic Resonance Imaging | 9 | 2022 | 35421 | 0.170 |
Why?
|
Orbital Fractures | 1 | 2020 | 110 | 0.170 |
Why?
|
Retinitis | 1 | 2019 | 35 | 0.170 |
Why?
|
Administration, Oral | 2 | 2018 | 3913 | 0.170 |
Why?
|
Eye Enucleation | 2 | 2016 | 128 | 0.170 |
Why?
|
Visual Acuity | 3 | 2017 | 2530 | 0.170 |
Why?
|
Glomerulonephritis, IGA | 1 | 2019 | 66 | 0.170 |
Why?
|
Female | 25 | 2022 | 380194 | 0.170 |
Why?
|
Hydrolysis | 1 | 2019 | 682 | 0.160 |
Why?
|
Diagnosis, Differential | 3 | 2019 | 12959 | 0.160 |
Why?
|
Adult | 16 | 2022 | 214055 | 0.160 |
Why?
|
Middle Aged | 19 | 2022 | 213383 | 0.160 |
Why?
|
Clindamycin | 1 | 2018 | 139 | 0.150 |
Why?
|
Dacryocystorhinostomy | 1 | 2018 | 72 | 0.150 |
Why?
|
Endoscopy | 3 | 2018 | 1785 | 0.150 |
Why?
|
Neoplasm, Residual | 1 | 2022 | 973 | 0.150 |
Why?
|
Male | 21 | 2022 | 350118 | 0.150 |
Why?
|
Port-Wine Stain | 1 | 2016 | 33 | 0.140 |
Why?
|
Optic Nerve Diseases | 1 | 2019 | 327 | 0.130 |
Why?
|
Acyclovir | 1 | 2016 | 272 | 0.130 |
Why?
|
Lymphangiogenesis | 1 | 2016 | 172 | 0.130 |
Why?
|
Nasal Mucosa | 1 | 2018 | 373 | 0.130 |
Why?
|
Herpesvirus 3, Human | 1 | 2016 | 204 | 0.130 |
Why?
|
Neovascularization, Pathologic | 2 | 2016 | 2635 | 0.130 |
Why?
|
Valine | 1 | 2016 | 413 | 0.120 |
Why?
|
Lacrimal Apparatus | 1 | 2016 | 225 | 0.120 |
Why?
|
Eyelashes | 1 | 2014 | 16 | 0.120 |
Why?
|
Bioartificial Organs | 1 | 2014 | 49 | 0.120 |
Why?
|
Injections | 1 | 2017 | 840 | 0.120 |
Why?
|
Prostaglandins, Synthetic | 1 | 2013 | 21 | 0.120 |
Why?
|
Hemangioma, Cavernous | 1 | 2014 | 110 | 0.120 |
Why?
|
Panophthalmitis | 1 | 2013 | 6 | 0.120 |
Why?
|
Tomography, X-Ray Computed | 7 | 2019 | 20129 | 0.110 |
Why?
|
Eye Burns | 1 | 2014 | 103 | 0.110 |
Why?
|
Viscosupplements | 1 | 2013 | 23 | 0.110 |
Why?
|
Eye Diseases | 1 | 2019 | 669 | 0.110 |
Why?
|
Orbital Cellulitis | 1 | 2013 | 33 | 0.110 |
Why?
|
Drug Combinations | 1 | 2018 | 1959 | 0.110 |
Why?
|
Skin Abnormalities | 1 | 2013 | 60 | 0.110 |
Why?
|
Burns, Chemical | 1 | 2014 | 159 | 0.110 |
Why?
|
Visual Fields | 1 | 2019 | 1047 | 0.100 |
Why?
|
Debridement | 1 | 2014 | 492 | 0.100 |
Why?
|
Inflammation | 2 | 2022 | 10638 | 0.100 |
Why?
|
Viral Load | 2 | 2017 | 3299 | 0.100 |
Why?
|
Botulinum Toxins | 1 | 2013 | 191 | 0.100 |
Why?
|
Aged, 80 and over | 5 | 2019 | 57776 | 0.090 |
Why?
|
Foreign Bodies | 1 | 2014 | 399 | 0.090 |
Why?
|
Prostheses and Implants | 1 | 2017 | 1387 | 0.090 |
Why?
|
Vaccination | 1 | 2022 | 3278 | 0.090 |
Why?
|
Molecular Biology | 1 | 2013 | 596 | 0.090 |
Why?
|
Cell Membrane Permeability | 1 | 2011 | 590 | 0.090 |
Why?
|
Nephritis, Hereditary | 1 | 2009 | 88 | 0.090 |
Why?
|
Microscopy, Electron, Scanning | 1 | 2011 | 964 | 0.080 |
Why?
|
Escherichia coli Infections | 1 | 2013 | 532 | 0.080 |
Why?
|
Neoplasm Invasiveness | 1 | 2017 | 3616 | 0.080 |
Why?
|
Herpesvirus 4, Human | 1 | 2014 | 1041 | 0.080 |
Why?
|
Adenoma | 1 | 2020 | 2174 | 0.080 |
Why?
|
Blindness | 1 | 2013 | 617 | 0.080 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2016 | 1676 | 0.080 |
Why?
|
Young Adult | 5 | 2018 | 56430 | 0.080 |
Why?
|
Glucocorticoids | 1 | 2018 | 2107 | 0.080 |
Why?
|
Eye Diseases, Hereditary | 1 | 2009 | 117 | 0.080 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2014 | 570 | 0.080 |
Why?
|
Retinal Pigment Epithelium | 1 | 2011 | 302 | 0.080 |
Why?
|
Suture Techniques | 1 | 2013 | 798 | 0.080 |
Why?
|
Retrospective Studies | 9 | 2023 | 77449 | 0.080 |
Why?
|
Corneal Diseases | 1 | 2014 | 636 | 0.070 |
Why?
|
Proteomics | 1 | 2020 | 3638 | 0.070 |
Why?
|
Cell Count | 1 | 2011 | 1856 | 0.070 |
Why?
|
Drug Synergism | 1 | 2011 | 1792 | 0.070 |
Why?
|
Postoperative Complications | 2 | 2019 | 15295 | 0.070 |
Why?
|
Neoplasm Metastasis | 1 | 2016 | 4851 | 0.070 |
Why?
|
Tomography, Optical Coherence | 2 | 2016 | 2657 | 0.070 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2014 | 1519 | 0.060 |
Why?
|
Flow Cytometry | 1 | 2016 | 5974 | 0.060 |
Why?
|
Pain | 1 | 2019 | 4986 | 0.060 |
Why?
|
Aged | 9 | 2022 | 163280 | 0.060 |
Why?
|
Diabetes Mellitus | 1 | 2022 | 5751 | 0.060 |
Why?
|
Antiviral Agents | 1 | 2016 | 2987 | 0.060 |
Why?
|
Quality Improvement | 1 | 2019 | 3749 | 0.060 |
Why?
|
Glaucoma | 1 | 2013 | 1159 | 0.060 |
Why?
|
Neoplasm Proteins | 1 | 2016 | 3703 | 0.060 |
Why?
|
Retinal Diseases | 1 | 2009 | 683 | 0.060 |
Why?
|
Tumor Cells, Cultured | 1 | 2011 | 6314 | 0.060 |
Why?
|
Carcinoma | 1 | 2013 | 2375 | 0.050 |
Why?
|
Disease Models, Animal | 1 | 2020 | 18029 | 0.050 |
Why?
|
Cell Survival | 1 | 2011 | 5882 | 0.050 |
Why?
|
B-Lymphocytes | 1 | 2014 | 4665 | 0.050 |
Why?
|
Asthma | 1 | 2019 | 6011 | 0.050 |
Why?
|
Sebaceous Glands | 1 | 2020 | 41 | 0.050 |
Why?
|
Anti-Bacterial Agents | 1 | 2018 | 7181 | 0.040 |
Why?
|
Drug Delivery Systems | 1 | 2011 | 2219 | 0.040 |
Why?
|
MutS Homolog 2 Protein | 1 | 2020 | 200 | 0.040 |
Why?
|
Disease Progression | 1 | 2015 | 13284 | 0.040 |
Why?
|
Ultrasonography | 1 | 2011 | 5985 | 0.040 |
Why?
|
Uncertainty | 1 | 2022 | 734 | 0.040 |
Why?
|
Treatment Outcome | 3 | 2019 | 63114 | 0.040 |
Why?
|
Hyperplasia | 1 | 2020 | 1185 | 0.040 |
Why?
|
Child | 2 | 2022 | 77709 | 0.030 |
Why?
|
Infant, Newborn | 1 | 2016 | 25625 | 0.030 |
Why?
|
Vascular Endothelial Growth Factors | 1 | 2016 | 772 | 0.030 |
Why?
|
Glass | 1 | 2014 | 114 | 0.030 |
Why?
|
Cloprostenol | 1 | 2013 | 22 | 0.030 |
Why?
|
Prostaglandins F, Synthetic | 1 | 2013 | 32 | 0.030 |
Why?
|
Child, Preschool | 1 | 2016 | 41006 | 0.030 |
Why?
|
Mice | 1 | 2020 | 81183 | 0.030 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 1 | 2016 | 664 | 0.030 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 1 | 2019 | 1184 | 0.030 |
Why?
|
Lymphatic Vessels | 1 | 2016 | 353 | 0.030 |
Why?
|
Blepharoptosis | 1 | 2013 | 143 | 0.030 |
Why?
|
Ophthalmoplegia | 1 | 2013 | 166 | 0.030 |
Why?
|
Immunoglobulin Heavy Chains | 1 | 2014 | 659 | 0.020 |
Why?
|
Mycoses | 1 | 2014 | 376 | 0.020 |
Why?
|
Amides | 1 | 2013 | 459 | 0.020 |
Why?
|
In Situ Hybridization | 1 | 2014 | 1950 | 0.020 |
Why?
|
Subcutaneous Fat | 1 | 2013 | 391 | 0.020 |
Why?
|
Decompression, Surgical | 1 | 2014 | 594 | 0.020 |
Why?
|
Gene Rearrangement | 1 | 2014 | 1179 | 0.020 |
Why?
|
Drainage | 1 | 2014 | 1142 | 0.020 |
Why?
|
Reoperation | 1 | 2018 | 4201 | 0.020 |
Why?
|
Animals | 1 | 2020 | 168757 | 0.020 |
Why?
|
Hyperpigmentation | 1 | 2009 | 112 | 0.020 |
Why?
|
Fluorescence | 1 | 2009 | 751 | 0.020 |
Why?
|
Breast Neoplasms | 1 | 2013 | 20822 | 0.020 |
Why?
|
Cornea | 1 | 2014 | 1524 | 0.020 |
Why?
|
Polymerase Chain Reaction | 1 | 2014 | 6171 | 0.020 |
Why?
|
Adipose Tissue | 1 | 2016 | 3279 | 0.020 |
Why?
|
Antibodies, Viral | 1 | 2014 | 3176 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 2016 | 11366 | 0.010 |
Why?
|
Age Factors | 1 | 2019 | 18370 | 0.010 |
Why?
|
Prospective Studies | 2 | 2019 | 53288 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2016 | 13033 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2013 | 12245 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2016 | 21746 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2018 | 39050 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2013 | 25043 | 0.010 |
Why?
|
United States | 1 | 2019 | 69872 | 0.010 |
Why?
|
Adolescent | 1 | 2014 | 85781 | 0.000 |
Why?
|
Concepts
(222)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(34)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_